"Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine
in HIV-1 Infected Men"
Dr. Stephen E. Goldstone, MD
Assistant Clinical Professor,
Mount Sinai School of Medicine Health
New York City, U.S.A.
Moderator Dr. Natasha Press, BCCfE
1. Summarize the burden of illness related to HPV in HIV infected men.
2. Discuss increased risk of HIV acquisition in HPV positive patients
3. Review safety and immunogenicity of the Quadrivalent HPV Vaccine in HIV Infected Men.
4. Discuss the opportunity to reduce personal risk of HPV infection and disease through vaccination in a high risk population.
Friday Dec. 9th 2011 12:00-1:00PM
Lunch will be served
Sheraton Wall Centre
Port Alberni Room
1088 Burrard St.
Please RSVP to Jodi Halsey-Brandt by Thursday Dec. 1st
firstname.lastname@example.org or 778-772-2447
Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer care and animal products, we work with customers and operate in more than
140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products
to the people who need them. Merck. Be Well. For more information, visit www.merck.com .